218 results
Page 2 of 11
8-K
EX-99.1
qbr4jn9ufac2k4yopn
7 Nov 23
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
9:08am
8-K
EX-99.1
vroat3 sj2abl
3 Aug 23
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
9:12am
8-K
EX-99.1
pzcgk1 trok9
5 Jul 23
Other Events
9:25am
8-K
EX-1.1
ygfsuq
1 May 23
Entry into a Material Definitive Agreement
5:26pm
424B5
nxgww1 arzc6b1k92
1 May 23
Prospectus supplement for primary offering
5:26pm
S-3ASR
jrin4 9devq4jgb9wcz
1 May 23
Automatic shelf registration
4:01pm
8-K
EX-99.1
poctu
1 May 23
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
9:05am
8-K
EX-10.1
w6d 3o22i0
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
424B5
917a9qng5bq0
21 Nov 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
wgi6nt8 ctlwn427s1
7 Nov 22
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
9:09am
8-K
EX-99.1
u377f5ni0ryjp05tewx7
3 Nov 22
Regulation FD Disclosure
9:26am
8-K
EX-99.1
7l85y91hnjdc 1s1dewa
3 Aug 22
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
9:25am
424B5
de1pbyar
29 Jul 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
1diuwx
5 May 22
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
9:04am